Volition's collaboration with Professor Lea Payen and Hospices Civils de Lyon.

Professor Lea Payen is an expert in molecular biology and toxicology and is leading the collaboration between Hospital of Lyon and Volition, to validate Volition's biomarker test.

This collaboration is a part of our strategy to attain certification under the In Vitro Diagnostic Regulation (IVDR), while also engaging industry leaders in the development and adoption of our transformative Nucleosomics technology in a range of exemplifications of our assays.

Working with centres of excellence, such as the Hospital of Lyon, and providing leading clinicians and researchers with exclusive, early access to our Nu.Q® product range, is an enormous step forward for Volition and a critical phase in our path ro commercialization. Professor Payen's team has been working on validating our Nucleosomics technology, focusing on its efficacy in lung cancer and NETosis.

"Overall, it's the best management of the patient... I hope it will be set up in laboratories all over the world." - Professor Lea Payen